Researchers at the Icahn School of Medicine at Mount Sinai have developed a powerful computational tool, named iDOMO, to ...

Researchers at Mount Sinai have developed iDOMO, a powerful AI tool that predicts synergistic drug combinations for complex ...

DCGI has sought post-market surveillance data from the drugmakers of two fixed-dose combination medicines—Imipramine ...

Researchers developed iDOMO, an AI-powered computational tool that predicts synergistic drug combinations using gene expression data. Validated in triple-negative breast cancer, iDOMO identified an ...

Researchers have developed a powerful computational tool, named iDOMO, to improve the prediction of drug synergy and accelerate the development of combination therapies for complex diseases. The study ...

In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments ...